B. subtilis

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Across the abstracts, Bacillus subtilis research is most developed in three applied areas: (i) probiotic use in animal production (especially poultry) to improve growth performance and intestinal health; (ii) mechanistic probiotic studies in tractable models (e.g., C. elegans) linking B. subtilis exposure to host pathways relevant to protein aggregation and aging; and (iii) biotechnology/industrial microbiology, where B. subtilis is a major chassis for recombinant protein production due to efficient secretion, established genetic tools, and generally recognized safety. Additional, but less fully detailed in the provided text, are agricultural/rhizosphere applications (seed coating, persistence, plant growth promotion/biocontrol) and aquaculture synbiotic strategies combining B. subtilis with other inputs (e.g., RNA) to support health in high-density culture systems.

The strongest evidence in these abstracts supports beneficial effects of dietary B. subtilis supplementation on poultry performance and gut health under both standard and disease-challenge conditions. Controlled broiler studies report improved feed conversion and body weight, improved intestinal morphology (increased villus height, reduced crypt depth), enhanced barrier-related gene expression (e.g., occludin), and immunological changes (cytokines, immunoglobulins), alongside shifts in gut microbiota including increased abundance of putative beneficial and butyrate-associated taxa. In a necrotic enteritis challenge model, a defined strain (DSM 32315) reduced lesion scores and mortality with performance outcomes comparable to an antibiotic growth promoter, supporting a plausible role as an antibiotic alternative in specific contexts. Mechanistic evidence is also emerging: in a C. elegans synucleinopathy model, multiple B. subtilis strains (spores and vegetative cells) reduced α-synuclein aggregation and promoted clearance of preformed aggregates, with partial dependence on host stress-response signaling (DAF-16), gut biofilm formation, bacterial metabolites, and host sphingolipid metabolism genes—providing a hypothesis-generating framework for neuroprotective potential.

Key research gaps include translation and generalizability: many probiotic findings are strain-, dose-, and context-dependent, and more work is needed to define which strains and formulations (spores vs vegetative cells; single vs multi-strain; engineered vs wild-type) reproducibly deliver benefits across breeds, diets, and management systems, and to establish causal mechanisms linking microbiome shifts to performance and immunity. For human health relevance, the neurodegeneration-related results are currently model-based; stronger evidence will require validation in mammalian systems and well-controlled clinical studies, alongside identification and quantification of active metabolites and host targets. In agriculture and aquaculture, persistence/colonization dynamics (e.g., rhizosphere survival after seed coating), ecological impacts, and long-term safety (including horizontal gene transfer risks for engineered delivery strains) remain under-characterized. Finally, in recombinant protein production, continued research is needed to mitigate proteolysis, improve secretion of difficult proteins, and optimize scalable fermentation and surface-display systems while maintaining genetic stability and product consistency.

1. What conditions has B. subtilis been studied for?

  • Protein aggregation / neurodegeneration models (Parkinson’s-related): Studied in a Caenorhabditis elegans synucleinopathy model where a probiotic strain (PXN21) affected α-synuclein aggregation.

  • Growth performance and gut health in poultry: Multiple broiler chicken studies evaluated feed conversion ratio (FCR), body weight gain, intestinal morphology (villus height/crypt depth), tight junction markers (e.g., occludin), immune markers (cytokines, immunoglobulins), and microbiota shifts.

  • Necrotic enteritis in poultry (Clostridium perfringens challenge): B. subtilis DSM 32315 tested in broilers under experimentally induced necrotic enteritis.

  • Coccidiosis / Eimeria infection in poultry (as a delivery platform): A recombinant B. subtilis expressing chicken NK-lysin peptide (B. subtilis-cNK-2) evaluated as an oral delivery system with therapeutic effects against Eimeria parasites.

  • Aquaculture immune support and disease resistance: Synbiotic combination of B. subtilis + RNA tested in Asian seabass, including survival after Aeromonas hydrophila challenge.

  • Heavy metal toxicity in fish: Evaluated for ameliorating lead (Pb)-induced toxicity in Carassius auratus gibelio (gibel carp) (abstract truncated but intent is explicit).

  • Food/feed fermentation and contamination risk: Used with Lactobacillus plantarum in solid-state fermentation of soybean meal to improve nutritional profile and reduce contamination/mycotoxin risk.

  • Agricultural plant growth promotion / rhizosphere persistence: Studied (with B. licheniformis) for tomato growth promotion and survival in shoots/rhizosphere after seed coating (abstract truncated).

  • Biotechnology (recombinant protein production): Reviewed as a host for recombinant protein expression/secretion and surface display (not a “condition,” but a major studied application).

2. Does it work in treating those conditions? Summarize the evidence.

  • α-synuclein aggregation in a Parkinson’s-related worm model: In the C. elegans synucleinopathy model, B. subtilis PXN21 inhibited α-synuclein aggregation and cleared preformed aggregates, with protection in young and aging animals. The effect was partly mediated by DAF-16, and multiple B. subtilis strains showed protection via both spores and vegetative cells, potentially involving gut biofilm formation and bacterial metabolites. Host pathways including sphingolipid metabolism were implicated (genes lagr-1, asm-3, sptl-3 had functional roles). This is promising mechanistic preclinical evidence, but it is not human clinical evidence.

  • Broiler growth performance and gut barrier outcomes: In a randomized broiler study with dual-strain B. subtilis at 300 or 500 mg/kg, the 500 mg/kg dose significantly reduced FCR by 4.55% during the starting phase, increased jejunal villus height (≈17.89% and 24.8%), decreased crypt depth (≈27.2% and 31.9%) at day 21, and increased occludin gene expression at day 35 (500 mg/kg). Immune markers (cytokines, immunoglobulins) increased, and microbiota shifts included higher abundance of putative beneficial taxa (e.g., Sutterella and butyrate producers such as Anaerostipes), with correlations between some taxa and performance/immune function.

  • Broiler growth performance and microbiota (single strain): In broilers given B. subtilis CGMCC 1.1086, daily weight gain was reported as 27.7% higher over 2 weeks and FCR improved by 10.3%. 16S data showed increased relative abundance of genera such as Alistipes, Odoribacter, Ruminococcus, Blautia, Desulfovibrio and decreased potential pathogens such as Staphylococcus and Escherichia-Shigella. This supports efficacy in poultry production contexts, not necessarily human health outcomes.

  • Necrotic enteritis (NE) in broilers: In two experiments, B. subtilis DSM 32315 supplementation in NE-challenged broilers improved outcomes versus infected controls, including higher body weight, lower mortality, and lower lesion scores. Histomorphometry showed shallower crypt depth and higher villus height:crypt depth ratio. Importantly, effects were described as comparable to bacitracin methylene disalicylate (BMD) on phenotypic/performance measures in these experiments.

  • Coccidiosis (Eimeria) using engineered B. subtilis: The abstract describes B. subtilis-cNK-2 as an oral delivery system with therapeutic effect against Eimeria parasites, and a follow-up study tested a higher dose and assessed coccidiosis, intestinal health, and microbiota (details truncated). This suggests efficacy in that animal model, but it involves a genetically engineered strain expressing an antimicrobial peptide, which is not equivalent to standard probiotic supplements.

  • Aquaculture immunity and pathogen challenge: In Asian seabass, a synbiotic of B. subtilis + RNA for 14 days increased multiple innate immune parameters (e.g., phagocytic activity/index, respiratory burst, serum lysozyme and bactericidal activity) and upregulated immune-related genes (e.g., HEPC1, A2M, C3, LYS, HSP70/90). It also increased ileal villus height and goblet cell numbers and improved survival after Aeromonas hydrophila challenge, with no reported histopathological abnormalities in intestine/liver in that study.

  • Lead toxicity in fish: The abstract indicates evaluation of B. subtilis for ameliorating Pb-induced toxicity in gibel carp, but the provided text is truncated and does not include outcomes; efficacy cannot be concluded from the excerpt.

  • IBD: An IBD-related abstract is present but truncated (“isolated a novel strain…”). No conclusions about efficacy can be drawn from the provided text.

3. What health benefits does it have?

  • Gut barrier and intestinal morphology support (animal evidence): In broilers, supplementation increased villus height and reduced crypt depth, and increased tight junction marker expression (occludin), consistent with improved barrier-related parameters.

  • Immune modulation (animal evidence): Broiler studies reported increased cytokines and immunoglobulins in serum and jejunal mucosa. In Asian seabass, multiple innate immune functions and immune gene expression were increased, alongside improved survival after bacterial challenge.

  • Microbiome modulation (animal evidence): Broiler studies reported increased abundance of taxa described as potential probiotics and butyrate producers (e.g., Sutterella, Anaerostipes and others) and reduced relative abundance of potential pathogens (e.g., Staphylococcus; Escherichia-Shigella).

  • Performance outcomes in livestock (applied benefit): Improved feed conversion ratio and weight gain were reported in broilers; in NE challenge models, B. subtilis DSM 32315 improved growth and reduced mortality/lesions, with effects comparable to an antibiotic growth promoter in those experiments.

  • Anti-protein aggregation effects in a model organism (preclinical): In C. elegans, B. subtilis reduced α-synuclein aggregation and promoted clearance of aggregates, with mechanistic links to host pathways (DAF-16; sphingolipid metabolism genes). This suggests potential neuroprotective mechanisms, but translation to humans is unknown based on these abstracts.

  • Food/feed processing benefits: In soybean meal fermentation, adding B. subtilis (with L. plantarum) increased crude protein/free amino acids and reduced crude fiber and phytic acid; starter addition helped prevent mycotoxin production and reduced Staphylococcus relative content.

4. Does it have any downsides or side effects?

  • Limited safety detail in the provided abstracts for humans: The excerpts largely involve animals, invertebrate models, or industrial/agricultural applications. They do not provide systematic reporting of adverse events in humans.

  • Generally recognized safety (contextual statement): One excerpt states B. subtilis is “recognized as generally safe” (text truncated), which aligns with its common use, but this is not the same as proving safety for all strains, doses, and populations.

  • Engineered strains are a special case: The cNK-2 work uses recombinant B. subtilis as a delivery system. Safety considerations for genetically modified strains (e.g., containment, gene transfer, regulatory status) differ from typical over-the-counter probiotic strains; the abstract does not provide detailed risk assessment.

  • Aquaculture study reported no histopathology signals: In Asian seabass, the synbiotic (B. subtilis + RNA) “did not cause histopathological abnormalities in the intestine and liver” over the study period, supporting short-term tolerability in that model.

  • Practical limitation/uncertainty: Effects appear strain-, dose-, and context-dependent (e.g., 500 mg/kg outperforming 300 mg/kg in broilers; different strains used across studies). This variability is a “downside” for predictability and generalization.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report human pharmacogenomic findings (i.e., differential efficacy or adverse effects by human genotype).

  • Model-organism genetics suggest host-pathway dependence: In the C. elegans synucleinopathy model, protection was partly mediated by DAF-16, and genes in sphingolipid metabolism (lagr-1, asm-3, sptl-3) were functionally involved. This implies that host genetic variation in analogous pathways could, in principle, influence response, but this is not demonstrated in humans in the provided material.

  • Bottom line: No actionable pharmacogenomic guidance (who benefits more/less based on genotype) can be concluded from these abstracts.

References

  1. Bacillus strains as human probiotics: characterization, safety, microbiome, and probiotic carrier.
    Na-Kyoung Lee, Won-Suck Kim, Hyun-Dong Paik (2019) - Food science and biotechnology
  2. Classification and Multifaceted Potential of Secondary Metabolites Produced by
    Sajid Iqbal, Farida Begum, Ali A Rabaan, Mohammed Aljeldah, Basim R Al Shammari, Abdulsalam Alawfi, Amer Alshengeti, Tarek Sulaiman, Alam Khan (2023) - Molecules (Basel, Switzerland)
  3. Bacillus subtilis Improves Immunity and Disease Resistance in Rabbits.
    Mengjiao Guo, Fahao Wu, Guangen Hao, Qin Qi, Rong Li, Ning Li, Liangmeng Wei, Tongjie Chai (2017) - Frontiers in immunology
  4. Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans.
    María Eugenia Goya, Feng Xue, Cristina Sampedro-Torres-Quevedo, Sofia Arnaouteli, Lourdes Riquelme-Dominguez, Andrés Romanowski, Jack Brydon, Kathryn L Ball, Nicola R Stanley-Wall, Maria Doitsidou (2020) - Cell reports
  5. Dietary probiotic based on a dual-strain Bacillus subtilis improves immunity, intestinal health, and growth performance of broiler chickens.
    Yuanli Cai, Chuanpi Xiao, Bo Tian, Sandvang Dorthe, Antoine Meuter, Bochen Song, Zhigang Song (2024) - Journal of animal science
  6. An overview and future prospects of recombinant protein production in Bacillus subtilis.
    Haiquan Yang, Jinfeng Qu, Wei Zou, Wei Shen, Xianzhong Chen (2021) - Applied microbiology and biotechnology
  7. Bacillus subtilis and Bacillus licheniformis promote tomato growth.
    Peterson S de O Nunes, Flavio H V de Medeiros, Tiago Sebastião de Oliveira, Jaqueline R de Almeida Zago, Wagner Bettiol (2023) - Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]
  8. Enhancement of gut barrier integrity by a
    Shiqi Liu, Peiran Cai, Wenjing You, Mingshun Yang, Yuang Tu, Yanbing Zhou, Teresa G Valencak, Yingping Xiao, Yizhen Wang, Tizhong Shan (2025) - iMeta
  9. Orally delivered Bacillus subtilis expressing chicken NK-2 peptide stabilizes gut microbiota and enhances intestinal health and local immunity in coccidiosis-infected broiler chickens.
    Samiru S Wickramasuriya, Inkyung Park, Youngsub Lee, Luciana M Richer, Chris Przybyszewski, Cyril G Gay, Jolieke G van Oosterwijk, Hyun S Lillehoj (2023) - Poultry science
  10. Effect of Bacillus subtilis DSM 32315 on the intestinal structural integrity and growth performance of broiler chickens under necrotic enteritis challenge.
    A O Sokale, A Menconi, G F Mathis, B Lumpkins, M D Sims, R A Whelan, K Doranalli (2019) - Poultry science
  11. Effects of ribonucleotide supplementation in modulating the growth of probiotic Bacillus subtilis and the synergistic benefits for improving the health performance of Asian seabass (Lates calcarifer).
    Jureerat Saengrung, Anurak Bunnoy, Xinmei Du, Lili Huang, Ran An, Xingguo Liang, Prapansak Srisapoome (2023) - Fish & shellfish immunology
  12. Effect of Bacillus subtilis CGMCC 1.1086 on the growth performance and intestinal microbiota of broilers.
    Y Li, Q Xu, Z Huang, L Lv, X Liu, C Yin, H Yan, J Yuan (2016) - Journal of applied microbiology
  13. Dietary host-associated
    Zhehui Ji, Chuanzhong Zhu, Xinyang Zhu, Sainan Ban, Lijuan Yu, Juan Tian, Lixue Dong, Hua Wen, Xing Lu, Ming Jiang (2023) - Animal nutrition (Zhongguo xu mu shou yi xue hui)
  14. Effect of Bacillus subtilis and Lactobacillus plantarum on solid-state fermentation of soybean meal.
    Qianqian Chen, Bo Liu, Guohong Liu, Huai Shi, Jieping Wang (2023) - Journal of the science of food and agriculture
  15. Effect of sub-chronic exposure to lead (Pb) and Bacillus subtilis on Carassius auratus gibelio: Bioaccumulation, antioxidant responses and immune responses.
    Yuwei Yin, Peijun Zhang, Xinyan Yue, Xiaoyan Du, Wei Li, Yulin Yin, Cheng Yi, Yuehong Li (2018) - Ecotoxicology and environmental safety
  16. Important role of Bacillus subtilis as a probiotic and vaccine carrier in animal health maintenance.
    Chunmei Yuan, Xiang Ji, Yuyu Zhang, Xinli Liu, Luogang Ding, Jianda Li, Sufang Ren, Fei Liu, Zhi Chen, Lin Zhang, Wenxing Zhu, Jiang Yu, Jiaqiang Wu (2024) - World journal of microbiology & biotechnology
  17. Effect of Bacillus subtilis Supplemented Diet on Broiler's Intestinal Microbiota and TLRs Gene Expression.
    Salman Khan, Anam Khalid, Ru Yang, Fatima Khalid, Muhammad Hamza Zahid, Haozhe Liu, Yunhua Zhang, Zaigui Wang (2024) - Probiotics and antimicrobial proteins
  18. Mixed
    Jun Chen, Liyu Mou, Lei Wang, Guofang Wu, Ximei Dai, Qiufang Chen, Jianbo Zhang, Xuan Luo, Fafang Xu, Miao Zhang, Yaoke Duan, Huili Pang, Yanping Wang, Yimin Cai, Zhongfang Tan (2024) - Frontiers in microbiology
  19. Autochthonous Bacillus subtilis and Enterococcus faecalis improved liver health, immune response, mucosal microbiota and red-head disease resistance of yellow drum (Nibea albiflora).
    Xi-Yue Ding, Cheng-Ye Wei, Zi-Yan Liu, Hong-Ling Yang, Fang Han, Yun-Zhang Sun (2023) - Fish & shellfish immunology
  20. Autolysis-mediated membrane vesicle formation in Bacillus subtilis.
    Kimihiro Abe, Masanori Toyofuku, Nobuhiko Nomura, Nozomu Obana (2021) - Environmental microbiology


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!